Teva announces the launch of the first generic version of absorica® (isotretinoin) capsules, for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older, in the united states

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced its launch of the first available 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg strength generic version of absorica®1 (isotretinoin) capsules for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. “teva's fir
TEVA Ratings Summary
TEVA Quant Ranking